<- Go Home

MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Market Cap

$102.7M

Volume

1.0M

Cash and Equivalents

$15.0M

EBITDA

-$30.3M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$24.6M

Profit Margin

79.23%

52 Week High

$1.86

52 Week Low

$0.64

Dividend

N/A

Price / Book Value

0.67

Price / Earnings

-2.98

Price / Tangible Book Value

0.67

Enterprise Value

$14.3M

Enterprise Value / EBITDA

-0.53

Operating Income

-$34.4M

Return on Equity

20.39%

Return on Assets

-10.64

Cash and Short Term Investments

$105.7M

Debt

$17.3M

Equity

$158.8M

Revenue

$31.1M

Unlevered FCF

-$13.1M

Sector

Life Sciences Tools and Services

Category

N/A

Company Stock Pitches